In the last trading session, 29.81 million shares of the Spruce Biosciences Inc (NASDAQ:SPRB) were traded, and its beta was 2.30. Most recently the company’s share price was $0.13, and it changed around -$0.18 or -58.02% from the last close, which brings the market valuation of the company to $5.45M. SPRB currently trades at a discount to its 52-week high of $0.87, offering almost -569.23% off that amount. The share price’s 52-week low was $0.26, which indicates that the current value has fallen by an impressive -100.0% since then. We note from Spruce Biosciences Inc’s average daily trading volume that its 10-day average is 3.37 million shares, with the 3-month average coming to 311.56K.
Spruce Biosciences Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 5 recommended SPRB as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Spruce Biosciences Inc is expected to report earnings per share of -0.2 for the current quarter.
Spruce Biosciences Inc (NASDAQ:SPRB) trade information
Instantly SPRB has showed a red trend with a performance of -58.02% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.3158 on recent trading dayincreased the stock’s daily price by 58.83%. The company’s shares are currently down -68.57% year-to-date, but still down -52.62% over the last five days. On the other hand, Spruce Biosciences Inc (NASDAQ:SPRB) is -60.05% down in the 30-day period. We can see from the shorts that 0.14 million shares have been sold at a short interest cover period of 0.72 day(s).
Spruce Biosciences Inc (SPRB) estimates and forecasts
The year-over-year growth rate is expected to be -67.42%, down from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 500k in revenue for the current quarter. 4 analysts expect Spruce Biosciences Inc to make 500k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2M and 1.61M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -75.02%. Forecasts for the next quarter put sales growth at -68.94%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -22.95%.
SPRB Dividends
Spruce Biosciences Inc’s next quarterly earnings report is expected to be released on 2025-Apr-14.
Spruce Biosciences Inc (NASDAQ:SPRB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.57% of Spruce Biosciences Inc shares, and 44.04% of them are in the hands of institutional investors. The stock currently has a share float of 49.81%. Spruce Biosciences Inc stock is held by 39.0 institutions, with RIVERVEST VENTURE MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 7.1449% of the shares, which is about 2.94 million shares worth $1.52 million.
CARLYLE GROUP INC., with 7.0481% or 2.9 million shares worth $1.52 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 638.56 shares worth $84289.0, making up 1.55% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 197.19 shares worth around $26028.0, which represents about 0.48% of the total shares outstanding.
